Ignore the noise in GLP-1 stocks. Find the best value instead.
Let's start with the background. Currently there are four branded and patent-protected GLP-1 weight-loss drugs on the market. Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE ...
Miguel Barclay has built a reputation on proving that good food doesn’t need to cost more than £1 a portion. Now, he’s ...
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...
A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...
“My background in biochemistry ... Working alongside a specialist diabetes dietitian at Novo Nordisk, he developed recipes that ticked every box: nutritious, affordable and, most importantly, ...
Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...
K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.
Novo Nordisk's insulin aspart franchise is a DKK ... Viatris' Semglee and Eli Lilly's Rezvoglar – which are used to provide a background level of insulin over the course of the day and reached ...